Press Releases InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-26 am EDT			5-day change	1st Jan Change
0.368 ^SEK	+5.14%		+11.85%	+43.75%

Apr. 26	InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 05	Index Pharmaceuticals Holding AB Announces Board Resignations	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InDex Pharmaceuticals Holding AB (publ) interim report January - March 2024	Apr. 26	AQ
InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024	Apr. 22	AQ
InDex Pharmaceuticals provides a company update	Apr. 08	AQ
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023	Apr. 08	AQ
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)	Apr. 05	AQ
CEO and CFO both to leave InDex Pharmaceuticals	Mar. 26	AQ
InDex Pharmaceuticals provides an update on company's future	Feb. 26	AQ
InDex Pharmaceuticals discontinues the development of cobitolimod	Feb. 26	AQ
InDex Pharmaceuticals Holding AB (publ) year-end report 2023	Feb. 21	AQ
InDex Pharmaceuticals announces expected cash balance per March 31, 2024	Jan. 19	AQ
InDex Pharmaceuticals Holding AB interim report January-September 2023	Nov. 29	AQ
InDex Pharmaceuticals Q3 2023 - Uncertain future post discontinuation of CONCLUDE	Nov. 29	AQ
InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023	Nov. 28	AQ
InDex Pharmaceuticals discontinues cobitolimod phase III program	Nov. 21	AQ
InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting	23-10-30	AQ
InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea	23-10-23	AQ
InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea	23-10-20	AQ
InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE	23-10-11	AQ
InDex Pharmaceuticals is attending the UEGW 2023 congress	23-10-05	AQ
InDex Pharmaceuticals Holding AB - Positive results from PK study with cobitolimod selected as one of the best abstracts for poster presentation at UEGW	23-08-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Press Releases

Filters